Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Pharmacoepidemiol Drug Saf. 2024 Aug;33(8):e5872. doi: 10.1002/pds.5872.
We aimed to validate and, if performance was unsatisfactory, update the previously published prognostic model to predict clinical deterioration in patients hospitalized for COVID-19, using data following vaccine availability.
Using electronic health records of patients ≥18 years, with laboratory-confirmed COVID-19, from a large care-delivery network in Massachusetts, USA, from March 2020 to November 2021, we tested the performance of the previously developed prediction model and updated the prediction model by incorporating data after availability of COVID-19 vaccines. We randomly divided data into development (70%) and validation (30%) cohorts. We built a model predicting worsening in a published severity scale in 24 h by LASSO regression and evaluated performance by c-statistic and Brier score.
Our study cohort consisted of 8185 patients (Development: 5730 patients [mean age: 62; 44% female] and Validation: 2455 patients [mean age: 62; 45% female]). The previously published model had suboptimal performance using data after November 2020 (N = 4973, c-statistic = 0.60. Brier score = 0.11). After retraining with the new data, the updated model included 38 predictors including 18 changing biomarkers. Patients hospitalized after Jun 1st, 2021 (when COVID-19 vaccines became widely available in Massachusetts) were younger and had fewer comorbidities than those hospitalized before. The c-statistic and Brier score were 0.77 and 0.13 in the development cohort, and 0.73 and 0.14 in the validation cohort.
The characteristics of patients hospitalized for COVID-19 differed substantially over time. We developed a new dynamic model for rapid progression with satisfactory performance in the validation set.
本研究旨在验证并更新之前发表的预测模型,以预测 COVID-19 住院患者的临床恶化情况,使用疫苗供应后的数据。
我们使用美国马萨诸塞州一个大型医疗服务网络的电子病历,对 2020 年 3 月至 2021 年 11 月期间≥18 岁、实验室确诊为 COVID-19 的患者进行了研究。我们对之前开发的预测模型进行了性能测试,并通过纳入 COVID-19 疫苗供应后的数据对预测模型进行了更新。我们将数据随机分为开发(70%)和验证(30%)两个队列。我们通过 LASSO 回归建立了一个预测 24 小时内恶化到既定严重程度的模型,并通过 C 统计量和 Brier 评分评估了模型性能。
本研究队列包括 8185 例患者(开发队列:5730 例患者[平均年龄:62 岁;44%为女性]和验证队列:2455 例患者[平均年龄:62 岁;45%为女性])。使用 2020 年 11 月以后的数据,之前发表的模型表现不佳(N=4973,C 统计量=0.60,Brier 评分=0.11)。在使用新数据进行重新训练后,更新后的模型纳入了 38 个预测因子,包括 18 个变化的生物标志物。2021 年 6 月 1 日(COVID-19 疫苗在马萨诸塞州广泛供应)之后住院的患者比之前住院的患者年龄更小,合并症更少。开发队列的 C 统计量和 Brier 评分分别为 0.77 和 0.13,验证队列的 C 统计量和 Brier 评分分别为 0.73 和 0.14。
COVID-19 住院患者的特征随时间发生了显著变化。我们开发了一个新的快速进展动态模型,在验证集上表现出令人满意的性能。